Loading clinical trials...
Loading clinical trials...
A Phase 1B/2A Study of the Safety, Tolerability and Initial Efficacy of Oral AMXT 1501 Dicaprate and Intravenous Difluoromethylornithine (DFMO) in Patients With Cancer
Conditions
Interventions
AMXT1501
DFMO
Locations
7
United States
Mayo Clinic - Arizona
Phoenix, Arizona, United States
Mayo Clinic - Florida
Jacksonville, Florida, United States
Mayo Clinic - Minnesota
Rochester, Minnesota, United States
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States
MD Anderson Cancer Center
Houston, Texas, United States
Fred Hutch Cancer Center - Seattle Cancer Care Alliance
Seattle, Washington, United States
Start Date
November 29, 2022
Primary Completion Date
December 12, 2024
Completion Date
December 12, 2024
Last Updated
December 24, 2024
NCT01109420
NCT07543159
NCT06713993
NCT07549477
NCT06340568
NCT06594926
Lead Sponsor
Aminex Therapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions